New state-of-the-art site opens in Carlsbad, California
Last month, we were delighted to open a state-of-the-art Innovation Lab in Carlsbad, California. The new 6,000 square foot, purpose-built site provides a base for our Volition America team, comprising colleagues who are specialists in R&D, Quality, and administration.
With dedicated open lab space and an additional four laboratories, our Carlsbad facility will enable the Volition team to remain at the forefront of understanding circulating nucleosomes, and how they can be utilized for disease screening and monitoring disease progression.
Working in collaboration
Our Innovation Team is led by Terry Kelly, our Chief Innovation Officer. The team works closely with our R&D colleagues based in Belgium, exploring basic molecular biology and cell biology including sequencing, undertaking cutting-edge discovery research, and taking forward strategic projects such as the development of Nu.Q® Capture. Terry explains more here.
Our Chief Operating Officer, Gaetan Michel, is excited about the expansion:
“The new space provides Volition America with its own premises at what is a crucial stage in the company’s development moving from an R&D company into commercialization. It will enable us to grow our team and future in a professional manner.”
Our new Head of Quality and Development Process, Sharon Ballesteros, will also be based at our Carlsbad facility. As an expert in quality assurance and process improvement, Sharon will work alongside our Belgian team on product realization and regulatory affairs. Sharon has already hit the ground running and is busy developing and implementing a robust clinical study and FDA regulatory program, to help bring our range of Nu.Q® products to market.
Joining San Diego’s biotech hub
Based at Carlsbad, our Volition America team is now part of a thriving local life sciences community, with over 400 biotechnology companies situated in the San Diego area, it is a center of excellence and talent.
Developing tests to detect life-altering diseases in both humans and animals, using our patented Nucleosomics™ technology, we look forward to becoming an indispensable part of that network.
